Aktienanalyse zu GH Research PLC (GHRS)GHRSGH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

GH Research PLC is a good buy right now due to its current price of $18.15, which is significantly below the analyst price target of $44, indicating a potential upside of 56%. Additionally, despite recent volatility with a 5-day change of -14.02%, the stock has shown a year-to-date increase of 37.08%, suggesting resilience. The RSI is at 16.764, indicating that the stock is oversold, which could present a buying opportunity. However, the main risk is the negative earnings trend, with a reported EPS of -0.23 in the last quarter, which could affect investor sentiment.